Analysts Bullish on Edgewise Therapeutics Stock

Firm's novel kidney disease drug candidate shows promise, boosting price targets

Apr. 13, 2026 at 10:10am

Got story updates? Submit your updates here. ›

A close-up image of intricate, industrial-looking mechanical components and machinery, conveying a sense of scientific precision and technological advancement in the pharmaceutical industry.Edgewise Therapeutics' innovative approach to targeting ion channels in rare diseases has analysts optimistic about the company's drug pipeline.Cambridge Today

Analysts have set a consensus price target of $38.44 for shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on rare kidney and neuromuscular diseases. The majority of analysts covering the stock have issued 'Buy' or 'Strong Buy' ratings, citing optimism around the company's lead drug candidate EWTX-101 for nephrotic syndromes.

Why it matters

Edgewise Therapeutics is developing a novel approach to treating severe kidney disorders, an area with significant unmet medical need. If successful, EWTX-101 could provide a new treatment option for patients suffering from debilitating conditions like focal segmental glomerulosclerosis (FSGS). The positive analyst sentiment suggests Wall Street sees strong commercial potential for the company's pipeline.

The details

Edgewise Therapeutics' lead drug candidate, EWTX-101, is an orally available inhibitor of the TRPC5 calcium channel, which has been implicated in nephrotic syndromes. The company is currently evaluating EWTX-101 in clinical trials for the treatment of FSGS and other proteinuric kidney diseases. Analysts have cited the drug's novel mechanism of action and Edgewise's expertise in small-molecule chemistry and ion channel biology as key factors driving their optimism.

  • Edgewise Therapeutics reported Q4 2025 earnings on February 26, 2026.
  • The company's stock price has risen over 30% year-to-date as of April 13, 2026.

The players

Edgewise Therapeutics, Inc.

A clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing precision medicines for rare kidney and neuromuscular diseases.

EWTX-101

Edgewise's lead drug candidate, an orally available inhibitor of the TRPC5 calcium channel that is being evaluated for the treatment of nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS).

Got photos? Submit your photos here. ›

What they’re saying

“We are very encouraged by the progress of EWTX-101 and believe it has significant potential to address the unmet needs of patients suffering from severe kidney disorders.”

— Badreddin Edris, Director, Edgewise Therapeutics

“Edgewise's innovative approach to targeting ion channels could lead to breakthroughs in rare disease treatment, and we are optimistic about the company's future prospects.”

— Analyst

What’s next

Edgewise Therapeutics is expected to provide an update on the clinical development of EWTX-101 at its annual investor day in June 2026.

The takeaway

Edgewise Therapeutics' focus on rare kidney and neuromuscular diseases, combined with its promising drug candidate EWTX-101, has garnered significant analyst support and optimism about the company's potential to deliver innovative treatments for patients with severe, unmet medical needs.